Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,119 | -19,770 | -1,354 | -6,519 | -9,636 |
| Depreciation Amortization | 238 | 1,096 | 852 | 613 | 326 |
| Accounts receivable | -3,288 | 66 | -3,910 | -2,168 | 597 |
| Other Working Capital | -6,624 | -21,195 | -24,209 | -3,605 | -2,713 |
| Other Operating Activity | 5,436 | 5,503 | 7,825 | 4,326 | 333 |
| Operating Cash Flow | $-19,358 | $-34,300 | $-20,797 | $-7,353 | $-11,092 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 16 | -829 | -272 | -233 | -203 |
| Investing Cash Flow | $16 | $-829 | $-272 | $-233 | $-203 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 83,125 | 4,749 | 4,142 | 3,447 | 1,869 |
| Financing Cash Flow | $83,125 | $4,749 | $4,142 | $3,447 | $1,869 |
| Beginning Cash Position | 52,826 | 82,756 | 83,256 | 83,256 | 83,256 |
| End Cash Position | 116,608 | 52,376 | 66,329 | 79,117 | 73,829 |
| Net Cash Flow | $63,783 | $-30,380 | $-16,927 | $-4,139 | $-9,427 |
| Free Cash Flow | |||||
| Operating Cash Flow | -19,358 | -34,300 | -20,797 | -7,353 | -11,092 |
| Capital Expenditure | N/A | -829 | -272 | -233 | -203 |
| Free Cash Flow | -19,358 | -35,129 | -21,068 | -7,586 | -11,295 |